two
recent
public
report
creation
ferrettransmiss
influenza
virus
controversi
exampl
research
aim
produc
sequenc
character
potenti
pandem
pathogen
ppp
novel
infecti
agent
known
like
effici
transmiss
among
human
signific
virul
limit
popul
immun
quantifi
possibl
novel
pathogen
could
accident
deliber
releas
exacerb
immunolog
vulner
human
popul
ppp
potenti
rapid
global
dissemin
via
everincreas
human
mobil
danger
hypothet
influenza
strain
respons
signific
morbid
mortal
around
world
thought
origin
laboratori
accid
risk
evalu
surround
biomed
research
kept
pace
scientif
innov
methodolog
applic
gap
particularli
disconcert
research
involv
construct
ppp
pose
risk
accident
releas
global
spread
argu
accept
principl
biomed
research
ethic
present
high
bar
ppp
experi
requir
risk
aris
experi
compens
benefit
public
health
achiev
safer
approach
focus
influenza
object
current
ppp
experiment
argu
safer
experiment
approach
scientif
inform
straightforward
translat
improv
public
health
enhanc
surveil
prevent
treatment
influenza
although
sever
pathogen
may
categor
ppp
see
box
gain
function
experi
involv
influenza
strain
modifi
ppp
expand
box
henc
immedi
concern
addit
two
controversi
studi
recent
publish
studi
use
similar
ferret
passag
protocol
still
other
creat
mammaliantransmiss
strain
vitro
follow
vivo
analysi
relat
studi
genet
combin
less
pathogen
zoonot
avian
virus
human
season
influenza
virus
gener
strain
exhibit
enhanc
transmiss
human
would
immunolog
suscept
studi
typic
conduct
biosafeti
level
bsl
contain
facil
laboratoryassoci
infect
facil
conserv
estim
occur
rate
two
per
laboratoryyear
unit
state
protocol
enforc
rel
stringent
global
highcontain
laboratori
variabl
standard
enforc
experiment
lessregul
unregul
laboratori
attend
risk
accident
deliber
releas
facilit
public
sequenc
function
data
ppp
even
origin
research
conduct
stateoftheart
safeti
secur
conserv
estim
rate
laboratoryassoci
infect
two
per
laboratoryyear
follow
moder
research
program
ten
laboratori
us
standard
decad
would
run
nearli
risk
result
least
one
laboratoryacquir
infect
turn
may
initi
chain
transmiss
probabl
laboratoryacquir
influenza
infect
would
lead
extens
spread
estim
least
simpl
branch
process
model
suggest
probabl
outbreak
aris
accident
influenza
infect
rang
probabl
ignor
multipli
potenti
devast
influenza
pandem
even
result
strain
substanti
attenu
observ
virul
highli
pathogen
influenza
subject
much
publish
ppp
work
date
advoc
dispassion
review
pertin
evid
calcul
probabl
magnitud
potenti
risk
parameter
specif
ppp
research
program
thu
far
experi
novel
ppp
assess
context
dual
use
research
concern
durc
design
research
could
use
good
bad
purpos
within
broader
categori
durc
ppp
experiment
rais
ethic
issu
deserv
extens
evalu
durc
scale
risk
pose
ppp
much
greater
durc
definit
present
risk
malevol
use
impact
accident
releas
mani
agent
involv
durcanthrax
hemorrhag
fever
virus
recent
novel
clostridium
botulinum
toxin
constrain
transmiss
mode
limit
host
suscept
magnitud
accident
risk
novel
ppp
much
greater
nuremberg
code
semin
document
clinic
research
ethic
specifi
research
conduct
human
particip
degre
risk
taken
never
exceed
determin
humanitarian
import
problem
solv
experi
broadli
nation
academi
scienc
state
scientist
oblig
harm
alway
take
consider
reason
forese
consequ
activ
ethic
principl
underli
guidelin
would
seem
appli
fortiori
research
impos
farreach
risk
public
given
global
natur
influenza
transmiss
thu
implic
beyond
countri
border
intern
agreement
regard
accept
risk
need
ethic
construct
risk
evalu
must
tailor
scientif
advanc
methodolog
applic
limit
attent
paid
ethic
scientif
experi
pose
risk
beyond
identifi
human
particip
practic
level
howev
spirit
nuremberg
code
humanitarian
import
criterion
embodi
recent
framework
evalu
ppp
experi
us
depart
health
human
servic
hh
primari
sponsor
experi
date
hh
framework
studi
anticip
creat
mammaliantransmiss
virus
specifi
risk
benefit
weigh
nuremberg
code
second
point
state
experi
yield
fruit
result
good
societi
unprocur
method
mean
studi
random
unnecessari
natur
project
benefit
experi
put
human
life
risk
therefor
critic
compar
altern
uniqu
public
health
benefit
ppp
experi
offer
rel
benefit
invest
equival
resourc
articl
describ
respons
ethic
scrutini
appli
experiment
studi
creat
employ
ppp
defin
ppp
infecti
agent
four
characterist
known
like
effici
transmiss
among
human
significantli
virul
unmitig
preexist
popul
immun
genet
distinct
pathogen
current
circul
criteria
defin
pathogen
experiment
would
pose
risk
spark
pandem
place
human
popul
risk
morbid
mortal
background
risk
natur
occur
pandem
paradigm
case
creation
variant
influenza
readili
transmiss
ferret
model
human
transmiss
criteria
would
like
applic
experiment
human
isol
smallpox
sar
sinc
pathogen
longer
known
circul
natur
futur
list
may
expand
advoc
necess
heighten
scrutini
isol
character
natur
occur
pathogen
wildtyp
consist
hh
framework
evalu
gainoffunct
studi
virus
exempt
character
natur
occur
virus
n
novel
ppp
research
program
moder
size
would
pose
substanti
risk
human
life
even
optimist
assum
low
probabl
pandem
would
ensu
laboratori
accid
n
altern
approach
would
safer
would
also
effect
improv
surveil
vaccin
design
two
purport
benefit
gainoffunct
experi
creat
novel
mammaliantransmiss
influenza
strain
n
rigor
quantit
imparti
riskbenefit
assess
preced
novel
ppp
experiment
case
influenza
anticip
risk
assess
show
risk
unjustifi
given
risk
global
pandem
pose
experi
risk
assess
part
broader
intern
discuss
involv
multipl
stakehold
domin
interest
perform
fund
research
altern
research
strategi
uniqu
benefit
novel
ppp
experi
justifi
risk
entail
concept
partial
incorpor
hh
framework
permit
fund
transmiss
gainoffunct
experi
feasibl
altern
method
address
scientif
question
manner
pose
less
risk
propos
approach
nuremberg
code
suggest
broader
criterion
ppp
experi
perform
public
health
benefit
envisag
obtain
safer
method
argu
altern
scientif
approach
less
riski
also
like
gener
result
readili
translat
public
health
benefit
propon
ppp
experiment
cite
two
main
benefit
studi
improv
interpret
surveil
data
detect
danger
virus
facilit
vaccin
develop
futur
natur
pandem
claim
disput
vaccin
claim
deni
vaccin
develop
note
mani
vaccin
develop
without
detail
molecular
understand
transmiss
advoc
ppp
experiment
argu
creat
potenti
pandem
strain
particular
viru
eg
could
facilit
product
stockpil
vaccin
variant
howev
given
ppp
experi
inevit
consid
possibl
genet
pathway
transmiss
precis
correspond
transmiss
ferret
model
human
transmiss
remain
uncertain
never
know
whether
ppp
experiment
would
hit
upon
antigen
composit
next
pandem
strain
emerg
natur
inde
describ
clear
onetoon
map
genet
chang
viru
transmiss
contrast
univers
influenza
vaccin
current
preclin
clinic
trial
may
develop
prove
worthwhil
stockpil
purpos
pandem
prepared
assort
vaccin
target
antigen
variant
manufactur
via
ppp
experiment
current
surveil
like
inadequ
detect
emerg
pandem
strain
late
regardless
warn
ppp
experiment
might
gener
potenti
worrisom
mutat
highli
pathogen
avian
influenza
almost
outbreak
involv
million
bird
report
world
organis
anim
health
us
nation
center
biotechnolog
inform
influenza
viru
resourc
receiv
complet
partial
avian
viru
sequenc
period
sequenc
eight
month
old
time
publicli
avail
influenza
viru
resourc
similar
consider
appli
gisaid
epiflu
databas
major
influenza
viru
sequenc
databas
given
bird
like
human
harbor
genet
divers
quasispeci
influenza
variant
highli
unlik
limit
surveil
could
detect
pandem
viral
sequenc
furthermor
spur
effect
mitig
action
worrisom
variant
alreadi
widespread
bird
exampl
limit
public
health
respons
even
danger
viru
observ
consid
global
respons
avian
influenza
proven
zoonot
potenti
probabl
repeatedli
transmit
human
human
isol
human
case
reveal
effici
bind
human
sialic
acid
receptor
airborn
transmiss
ferret
guinea
pig
indic
pandem
potenti
much
stronger
sequenc
comparison
engin
virus
could
provid
yet
live
bird
market
china
remain
open
human
case
continu
emerg
given
realiti
difficult
envis
surveil
signal
alon
would
prompt
swifter
action
exist
warn
sign
short
benefit
public
health
scientif
find
ppp
experiment
specul
best
challeng
realiz
public
health
benefit
ppp
experiment
predict
phenotyp
viral
sequenc
complex
demonstr
recent
assess
gener
mutat
confer
human
receptor
bind
engin
ferrettransmiss
strain
mutat
introduc
genet
background
recent
avian
isol
affin
human
receptor
lost
instead
phenotyp
mutat
depend
interact
genet
background
phenomenon
known
epistasi
observ
broadli
natur
influenza
virus
specif
tabl
thu
unlik
catalog
mutat
could
inform
reliabl
predict
transmiss
phenotyp
circul
strain
promin
role
epistasi
influenza
biolog
suggest
altern
approach
studi
phenotyp
impact
mutat
mammalian
transmiss
would
less
riski
also
inform
vivo
replic
transmiss
influenza
human
depend
myriad
interdepend
factor
includ
bind
affin
hemagglutinin
human
sialic
acid
abil
virion
fuse
endosom
membran
appropri
ph
temperatur
well
stabil
variou
viral
protein
trait
turn
simpli
determin
presenc
absenc
individu
amino
acid
box
gain
function
name
recent
ferret
transmiss
experi
influenza
virus
term
gain
function
experi
involv
engin
virus
gain
transmiss
ferret
gain
function
common
import
approach
biolog
experiment
caus
concern
howev
elev
concern
experi
aris
particular
function
gain
ferret
transmiss
thought
good
albeit
imperfect
model
humantohuman
transmiss
consequ
strain
result
select
heighten
ferret
transmiss
like
similarli
transmiss
human
via
respiratori
droplet
prerequisit
pandem
spread
combin
demonstr
virul
human
particular
gain
function
present
uniqu
risk
rais
special
ethic
issu
particular
site
biophys
properti
aris
interact
mani
site
within
protein
consequ
challeng
predict
transmiss
hing
understand
genet
determin
trait
coupl
interact
trait
higherlevel
phenotyp
transmiss
aris
array
safer
approach
tabl
studi
influenza
pathogenesi
transmiss
focu
dissect
interact
approach
start
sequenc
analysi
molecular
dynam
model
intrins
safe
experiment
evalu
hypothes
rais
studi
may
use
viral
compon
rather
entir
infecti
viru
make
experi
simultan
safer
precis
mechanist
engin
ppp
furthermor
approach
typic
less
costli
ppp
experiment
facilit
phenotyp
evalu
greater
divers
abund
genet
variant
ultim
studi
intact
virus
necessari
full
understand
human
transmiss
unaffect
virul
transmiss
decreas
fit
older
na
oseltamivir
resist
fit
crippl
oseltamivir
resist
fit
increas
absenc
drug
ha
ls
mammalian
transmiss
indonesia
viet
nam
switch
mammalian
sialic
acid
bind
egypt
polybas
ha
cleavag
site
high
avian
pathogen
mani
virus
low
avian
pathogen
four
isol
ha
hemagglutinin
na
neuraminidas
tabl
safer
approach
studi
human
adapt
influenza
virus
gener
improv
vaccin
therapeut
analysi
adapt
chang
ha
lipid
tail
protrus
determin
hamembran
fusion
identifi
determin
inhibitorresist
na
biophys
basi
complex
phenotyp
vitro
studi
specif
properti
requir
human
adapt
use
singl
protein
studi
receptor
bind
mammalian
versu
human
sialic
acid
studi
genet
determin
optim
ph
fusion
compar
properti
natur
isol
higher
throughput
vivo
studi
studi
sequenc
defin
motif
requir
bind
beyond
individu
mutat
abil
assess
gener
hypothes
determin
vitro
studi
genet
interact
loci
one
sever
viral
protein
use
replicationincompet
virus
studi
epistat
interact
nucleoprotein
nucleoprotein
polymeras
base
vitro
express
marker
stabil
measur
protein
higher
throughput
abil
link
structur
function
abil
test
combin
mutat
sequenc
databas
comparison
genet
properti
humanand
avianadapt
virus
identifi
amino
acid
marker
host
adapt
quantifi
extent
adapt
particular
host
search
marker
human
adapt
establish
earlier
studi
without
ppp
product
virus
high
throughput
futur
studi
could
use
novel
analyt
method
phenotyp
whole
viru
elucid
evolutionari
trajectori
exist
season
former
pandem
virus
becam
transmiss
avian
precursor
safer
ppp
experiment
given
preexist
popul
immun
season
strain
product
evolut
gener
rememb
public
health
goal
curtail
influenza
pandem
season
transmiss
explor
basic
biolog
one
scientif
mean
end
approach
develop
univers
influenza
vaccin
novel
antivir
drug
strategi
enhanc
host
respons
well
improv
technolog
rapid
vaccin
manufactur
pursu
without
risk
ppp
releas
tabl
urg
propos
futur
experi
ppp
evalu
accord
quantit
riskbenefit
analysi
guid
principl
nuremberg
code
inde
hh
framework
requir
riskbenefit
analysi
approv
gainoffunct
experiment
virus
yet
analysi
made
public
conduct
fund
regulatori
agenc
yet
call
riskbenefit
analysi
requir
one
well
biomed
grant
review
process
propos
compet
limit
fund
propos
could
advanc
scienc
never
support
budget
constraint
fund
agenc
conclud
promis
safer
human
otherwis
superior
way
achiev
scientif
goal
ppp
experiment
pose
signific
risk
public
health
arguabl
highest
level
risk
pose
biomed
research
experi
assess
basi
margin
benefit
compar
safer
approach
case
influenza
given
higher
throughput
lower
cost
altern
believ
benefit
altern
approach
greater
novel
ppp
experiment
yet
without
riskstherebi
negat
justif
take
risk
similarli
care
consider
given
analys
novel
ppp
experi
beyond
studi
influenza
propos
funder
regul
evalu
balanc
risk
benefit
novel
ppp
experi
undertaken
